Ro Khanna bought Agios Pharm (NASDAQ: AGIO)
Ro Khanna (D-CA), a U.S. Representative, has disclosed 1 trade in Agios Pharm (AGIO) since 2022, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Ro Khanna bought $1,001 - $15,000 of Agios Pharm (NASDAQ: AGIO) on April 17, 2022. Since that trade, AGIO is up +17.38% against the S&P 500 up +79.04%, an outperformance of -61.66%.
Data updated
Ro Khanna's AGIO trades vs the price
AGIO is up +17.38% since Ro Khanna bought on April 17, 2022, versus +79.04% for the S&P 500.
Performance since this trade
All Ro Khanna AGIO trades
Ro Khanna & AGIO trading FAQ
Is it legal for Ro Khanna to trade Agios Pharm (AGIO) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Agios Pharm (AGIO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Ro Khanna buy AGIO?
Ro Khanna disclosed a purchase of $1,001 - $15,000 of Agios Pharm (AGIO) on April 17, 2022, according to public STOCK Act filings.
How has AGIO performed since Ro Khanna's trade?
Since Ro Khanna bought AGIO on April 17, 2022, the stock is up +17.38%, versus +79.04% for the S&P 500 over the same period, an outperformance of -61.66%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AGIO trades?
Quantellect tracks every disclosed congressional trade in Agios Pharm (AGIO) on the Agios Pharm congressional trading page, which aggregates filings across all members of Congress.
Ro Khanna's AGIO tradesAll congressional filings for Agios PharmRo Khanna's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.